Molecular biology of Burkitt's lymphoma

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3707-3721

  Hecht, Jonathan L ^a   Aster, Jon C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; LEUCINE ZIPPER PROTEIN; MYC PROTEIN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL PROLIFERATION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034327890     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3707     Document Type: Article

References (151)

1. Summary and description of a working formulation for clinical usage - The Non-Hodgkin's Lymphoma Pathologic Classification Project
2. A revised European-American classification of lymphoid neoplasm: A proposal from the International Lynphoma Study Group
3. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen
4. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells
5. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells
6. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 105 patients (1981-1986)
7. Burkitt-like lymphomas in AIDS patients: Characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas - Burkitt's Lymphoma Study Group
8. AIDS-related lymphoma: Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization
9. Lymphomas associated with HIV infection
10. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: A single-institution clinicopathologic study of 75 patients
11. African Burkitt's lymphoma: History, biology, clinical features, and treatment
12. Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas
13. Jaw involvement in American Burkitt's lymphoma
14. Central nervous system involvement in American Burkitt's lymphoma
15. Molecular epidemiology of Burkitt's lymphoma from South America: Differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions
16. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma
17. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma: Cor-relation of lymphoma phenotype with three distinct pattems of viral latency
18. Histogenetic correlations between subcategories of small noncleaved cell lymphomas
19. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas
20. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malig nancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11)
21. Malignant lymphomas with band 8q24 chromosome abnormality: A morphologic continuum extending from Burkitt's to immunoblastic lymphoma
22. Variant (8;22) translocation in lymphoblastic lymphoma
23. Small noncleaved, non-Burkitt's (Burkitt-Like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation
24. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene
25. Cytogenetic findings in 200 patients with multiple myeloma
26. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
27. The role of somatic hypermutation in the generation of antibody diversity
28. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma
29. Complete nucleotide sequence of Ig V genes in three cases of Burkitt lymphoma associated with AIDS
30. The immunology of AIDS-associated lymphomas
31. Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis
32. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection
33. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma
34. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus
35. Subtracted, uniquesequence, in situ hybridization: Experimental and diagnostic applications
36. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma
37. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma
38. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: Relevance to geography and Epstein-Barr virus association
39. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb
40. The pathogenesis of Burkitt's lymphoma
41. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma
42. The t(8;14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V-D-J joining
43. The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region
44. Reexpression of RAG-1 and RAG- 2 genes in activated mature mouse B cells
45. V(D)J recombinase activity in a subset of germinal center B lymphocytes
46. Expression and function of recombination activating genes in mature B cells
47. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development
48. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu)
49. Immunoglobulin gene transcription ceases upon deletion of a distant enhancer
50. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL 60 cells
51. Phosphorylation-dependent binding of a 138-kDa myc intron factor to a regulatory element in the first intron of the c-myc gene
52. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma
53. A point mutation in the c-myc locus of a Burkitt lymphoma abolishes binding of a nuclear protein
54. Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome
55. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc
56. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover
57. c-Myc proteolysis by the ubiquitinproteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells
58. Function of the c-Myc oncogenic transcription factor
59. c-Myc target genes involved in cell growth, apoptosis, and metabolism
60. New Myc-interacting proteins: A second Myc network emerges
61. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max
62. Max: Functional domains and interaction with c-Myc
63. Oncogenic activity of the c-Myc protein requires dimerization with Max
64. Binding of myc proteins to canonical and noncanonical DNA sequences
65. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max
66. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo
67. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity
68. Two MAD tails: What the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network
69. Mnt: A novel Maxinteracting protein and Myc antagonist
70. Chromatin remodeling and leukemia: New therapeutic paradigms
71. Role of histone deacetylases in acute leukemia
72. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN 3
73. Sin3 corepressor function in Myc-induced transcription and transformation
74. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
75. A complex containing N-CoR, mSin 3 and histone deacetylase mediates transcriptional repression
76. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity
77. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E 2F oncoproteins
78. Tra 1p is a component of the yeast Ada.Spt transcriptional regulatory complexes
79. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: Characterization of an Ada complex and the SAGA (Spt/Ada) complex
80. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc
81. Myc and Max proteins possess distinct transcriptional activities
82. Myc-mediated transformation: The repression connection
83. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
84. Transcriptional control of the endogenous MYC protooncogene by antisense RNA
85. c-Myc antisense transcripts accelerate differentiation and inhibit G 1 progression in murine erythroleukemia cells
86. Regulation of cell cycle duration by c-myc levels
87. Dissection of c-myc domains involved in S phase induction of NIH 3T3 fibroblasts
88. c-Myc regulates cyclin D-Cdk4 and -Cdk 6 activity but affects cell cycle progression at multiple independent points
89. Myc function and regulation
90. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk 2 complexes
91. Cdc25 cell-cycle phosphatase as a target of c-myc
92. Transient excess of MYC activity can elicit genomic instability and tumorigenesis
93. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II
94. A novel function for Myc: Inhibition of C/EBP-dependent gene activation
95. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice
96. Reversible tumorigenesis by MYC in hematopoietic lineages
97. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth
98. The ornithine decarboxylase gene is a transcriptional target of c-Myc
99. c-Myc binds to 5' flanking sequence motifs of the dihydrofolate reductase gene in cellular extracts: Role in proliferation
100. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants
101. Myc versus USF: Discrimination at the cad gene is determined by core promoter elements
102. Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase
103. c-Myc target gene specificity is determined by a post-DNA binding mechanism
104. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets
105. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc
106. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast
107. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc
108. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC
109. Mediation of c-Myc-induced apoptosis by p 53
110. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
111. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
112. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53
113. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
114. Apoptotic cell death induced by c-myc is inhibited by bcl- 2
115. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
116. Cellular oncogenes and multistep carcinogenesis
117. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
118. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
119. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc
120. Oncogenic ras provokes premature cell senescence associated with accumulation of p 53 and p16INK4a
121. Myc activates telomerase
122. Direct activation of TERT transcription by c-MYC
123. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT)
124. 17p anomalies in lymphoid malignancies: Diagnostic and prognostic implications
125. p53 Mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
126. Mutations of the p53 gene in B-cell lymphoma
127. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma
128. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells
129. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation
130. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
131. Death associated proteins (DAPs): From gene identification to the analysis of their apoptotic and tumor suppressive functions
132. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain
133. Point mutations of the BCL-6 gene in Burkitt's lymphoma
134. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia
135. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 New reports and a review of 148 cases from the literature
136. Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines
137. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
138. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation
139. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes
140. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue
141. The roles of human viruses in the pathogenesis of lymphoma
142. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro
143. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus
144. Expression of Epstein-Barr virus nuclear antigen- 1 induces B cell neoplasia in transgenic mice
145. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata
146. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma
147. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
148. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
149. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
150. Study of Burkitt lymphoma cell line proteins by high resolution two-dimensional gel electrophoresis and nanoelectrospray mass spectrometry
151. Tissue microarrays for high-throughput molecular profiling of tumor specimens